CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

A Winnipeg couple has temporarily relocated to Memphis, Tennessee, in search of lifesaving treatment for their 3-year-old son ...

Researchers from The University of Osaka identify a molecule that can support specific therapeutic targeting of AML with ...

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Syndax has a strong cash position and a significant market opportunity with Revuforj and Niktimvo. Check out my ...

About 6% of pregnancy-related cancers are Hodgkin lymphoma, and 5% are non-Hodgkin lymphoma. Leukemias in pregnancy are rarer ...

The response rate was notable across various genetic mutations, with 75% of patients with myelomonocytic AML responding to the treatment ... for GPS in Acute Myeloid Leukemia without modifications ...